2019 POSTER PRESENTATIONS
Room: Commonwealth Hall

Presenting Monday through Thursday

908 Devices, Inc.
101.     An Integrated Benchtop Analyzer for the Rapid Analysis of Amino Acids, Water Soluble Vitamins, Biogenic Amines and Dipeptides in Cell Growth Media; Presented by Kerin G.

908 Devices, Inc.
102.     Rapid At-Line Nutrient Profiling from an Ammonia Stressed CHO Cell Line Utilizing an Integrated Benchtop Analyzer; Presented by Glenn H.

AbbVie
103.     Optimizing Key Amino Acids in CHO Cell Culture Medium Improves Productivity and Reduces Waste Byproducts for Biologics Manufacturing; Presented by Adam D.

Alphalyse A/S
104.     HCP Coverage by Immunocapture and LC-MS/MS; Presented by Ejvind M.

Applied Genetic Technologies Corporation
105.     Potency Assay Development for rAAV Vector Encoding ATP Binding Cassette Subfamily D Member 1 Protein (ALDP); Presented by Geeta I.

Applied Photophysics, Inc.
106.     More Than Just Alpha-Helix and Beta-Sheet: Expanding the Role of Circular Dichoism; Presented by Frank Y.

Aragen Bioscience, Inc.
107.     An Integrated Stepwise Approach to Developability Assessment of Therapeutic Antibody Candidates from Discovery to Development; Presented by Amisha K.

AstraZeneca
108.     Evaluation of a Novel Instrument for Automated Buffer Preparation; Presented by Mariko C.

AstraZeneca
109.     Evaluation of Flocculation as an Impurity Clearance Technique for Improved CHO Cell Culture Harvest; Presented by Valeria R.

Bilfinger Industrietechnik Salzburg GmbH
110.     A Software Implementing Quality by Control to Bioprocesses; Presented by Gerald B.

Bilfinger Industrietechnik Salzburg GmbH
111.     Oxygen Uptake Rate Soft-Sensing and Its Application for Biomass and Metabolic Transition Prediction; Presented by Wolfgang S.

Bristol-Myers Squibb
112.     Evaluation of a Multimodal Chromatography Capability for Host Cell Protein Clearance; Presented by Haiying B.

Bristol-Myers Squibb
113.     Application of a Relative Transcript Real-Time PCR Method in Predicting High-Expressing Clones During Cell Line Development; Presented by Erik L.

Bristol-Myers Squibb
114.     Viscosity in High-Concentration Protein Formulations; Presented by Thomas P.

Bristol-Myers Squibb
115.     Influence of Process and Analytical Factors on Charge Heterogeneity in Therapeutic Fusion Proteins; Presented by Ashwitha R.

Bristol-Myers Squibb
116.     Anion Exchange Design Space Optimization for Improving Process Robustness and Yield; Presented by Dong Y.

Celgene Corporation
117.     Development of a Rapid Peptide Mapping Method, Using Scaled Down Gradient, to Support Biologics Development; Presented by Nandakumar M.

Chung-Ang University
118.     Optimized Production and Quantification of the Sweet-Tasting Protein Brazzein in Kluyveromyces lactis; Presented by Kwang-Hoon K.

Corning, Inc.
119.     A Novel Method for AAV Vector Production Using Dissolvable Microcarriers; Presented by Hannah G.

DAICEL Bioseparations/Chiral Technologies, Inc.
120.     DAISEP MabXpure: Innovative Strategies for Enhancing HCP Clearance in Clarification and Downstream Processing of mAbs; Presented by Jerry R.

Development Center for Biotechnology
121.     A New CHO Expression System (CHO-C) and Integrated Continuous Bioprocessing Platform for High Yield Mab Production; Presented by Ching-Jen Y.

DuPont
122.     Dynamic Properties of a Novel Surfactant for Improved Biologic Stability; Presented by Susan J.

Fluid Imaging Technologies
123.     Comparison of Manual Pipetting Versus Automated Liquid Handler Pipetting into FlowCam; Presented by Dave H.

Fluid Imaging Technologies
124.     FlowCam Nano Provides Counts, Sizes and Images of Nano- and Microparticles: Application to a Therapeutic Protein Pumping Study; Presented by Dave H.

Genentech, Inc.
125.     Fast On-Line Characterization of Therapeutic Protein Charge Variants by Multi-Dimensional LC/MS; Presented by Lu D.

GenScript USA, Inc.
126.     Biologics and Viral Vectors for IND Application: CMC Platform by GenScript; Presented by Leon S.

GigaGen, Inc.
127.     An Optimized Targeted Integration CHO Cell Line for Manufacturing Polyclonal Antibodies; Presented by Jackson L.

Gilead Sciences, Inc.
128.     Applying High Throughput Particle Characterization Methods to Assess the Relative Titer and Physical Stability of Viral Vectors; Presented by Lydia S.

Gyros Protein Technologies
129.     Boosting Impurity Detection Productivity Using New Immunoassay Kits for HCP Analysis and Gyrolab® Automated Systems; Presented by Eric F.

Iuliu Hatieganu University of Medicine and Pharmacy
130.     Emulsion Monolayer Self-Assembly: A New Tool for Biomolecular Separation and Selective Recovery; Presented by Titus o.

JSR Life Sciences
131.     Protein A Chromatography as Capture Step for Antibody Fragments: Mechanism of Interaction and Case Study; Presented by Gary D.

Kaneka Americas Holding
132.     Concisely Produced Homogeneous Antibody-Drug Conjugates by A Tryptophan-Selective Protein Bioconjugation; Presented by Harkewal S.

Kite, a Gilead Company
133.     Development of a B Cell Flow Cytometric Method Intended for the Characterization of Incoming Patient Apheresis Materials; Presented by Michelle T.

KTH Royal Institute of Technology
134.     Optimization of a Calcium-Dependent Protein A-Derived Domain for Mild Antibody Purification; Presented by Julia S.

Lindy Biosciences, Inc.
135.     High-Concentration Suspensions of Protein Particles Produced by Microglassification; Presented by Michael D.

Lindy Biosciences, Inc.
136.     Microglassification: A Novel and Rapid Dehydration Technology; Presented by Adam R.

Lonza Biologics
137.     Feedback Control of Fed-Batch Mammalian Cell Culture Using Raman Spectroscopy; Presented by Brian H.

Magenta Therapeutics
138.     Systematic Formulation Development for Antibody Bulk Intermediate for Storage Before ADC Manufacturing; Presented by Ryan K.

MaxCyte, Inc.
139.     Strategies for Improved Protein Expression, Production Timelines and Laboratory Productivity Using CHO Cell Transient Expression; Presented by James B.

MaxCyte, Inc.
140.     Optimizing HEK and CHO Cell Line Stable Pool Generation Using Scalable Electroporation; Presented by Joan H.

MaxCyte, Inc.
141.     CRISPR-Based Engineering of CHO Cell Lines; Presented by Martin W.

Merck & Co., Inc.
142.     Development of a Robust Functional Cell-Based Assay for Replacing the Rabbit Blood Sugar Bioidentity Test of Insulin and Its Analog; Presented by Junming Y.

Microsaic Systems plc
143.     The Development of a Point-of-Need Miniaturized ESI-MS for Upstream Bioprocessing Applications; Presented by Alex M.

Molecular Devices, LLC
144.     High Throughput Sialylation Measurement on Octet Label Free Instrument for Cell Line Development; Presented by Hongshan L.

Molecular Devices, LLC
145.     Combining Single-Cell Isolation and Microplate Imaging to Increase Colony Outgrowth Efficiency with Higher Assurance of Clonality; Presented by Hongshan L.

MorphoSys AG
146.     How to Analyze and Influence Self-Interaction Behavior of mAbs - A Case Study; Presented by Martin D.

NanoCellect Biomedical, Inc.
147.     WOLF Cell Sorter for Single-Cell Cloning and Cell Line Development; Presented by Aly K.

Neofluidics LLC
148.     A Low-Volume, Multiplexed Microfluidic Viscometer for Protein Viscosity and Stability Characterization; Presented by Lisa L.

North Carolina State University
149.     Development of a Scalable Gene Therapy Vector Production Platform for Bioprocess Research and Training; Presented by Caroline S.

Novadip Biosciences
150.     An Allogenic 3D Scaffold-Free Tissue Engineered Product for Deep Thickness Skin Regeneration: In Vitro Development to In Vivo Proof of Concept; Presented by Nicolas T.

Pennsylvania State University
151.     A Two-Step Model for Colloidal Phase Separation in Therapeutic Antibody Solutions; Presented by Bradley R.

PerkinElmer
152.     Detection of AAV Capsid Proteins by CE-SDS as an Alternative to Silver Stain SDS-PAGE; Presented by Jeray T.

Polyplus-transfection
153.     Addressing Large-Scale Therapeutic Virus Production Using High Quality Grade PEI-Based Transfection Reagents; Presented by Jonathan H.

ProZyme, A Part of Agilent
154.     An Improved Workflow for Profiling and Quantitation of Sialic Acids in Biotherapeutics; Presented by Anna F.

Sartorius Stedim Biotech GmbH
155.     Single-Use Membrane Chromatography in ADC Production: Development of an ADC Process with Single-Use Membrane Chromatography Sartobind® S and Sartobind® Phenyl; Presented by Kathryn S.

Sartorius Stedim North America, Inc.
156.     Approaches for Applying Perfusion Mimic in the New ambr® 15 Cell Culture Generation 2; Presented by Ryan C.

Sartorius Stedim North America, Inc.
157.     Increased Productivity with Single-Use Membrane Chromatography; Presented by Daniela S.

SCIEX
158.     Quantitative LC-MS/MS Solution for Targeted Cell Culture Media Analysis; Presented by Yi Z.

Shire HGT, Inc., A Takeda Company
159.     Multimodal Chromatography in Fc-Fusion Protein Fragment Removal; Presented by Rongxin S.

Stanford University
160.     Manufacturing and Characterization of Bispecific CD19/22 CAR T for B-Cell Malignancies; Presented by Shabnum P.

Takeda Pharmaceuticals International, Inc.
161.     Evaluation of Gyros xPlore for Higher Throughput Host Cell Protein Measurement; Presented by Wenlan Y.

Thermo Fisher Scientific, Inc.
162.     Automated Foam Control in HyPerforma™ Single-Use Bioreactors Using a Single-Use Foam Probe; Presented by Josh A.

Thermo Fisher Scientific, Inc.
163.     Mixing Operations for 50 L to 2000 L Single-Use Mixer: Liquid-Liquid Mixing Characterization and Slurry Suspension; Presented by Josh A.

Thermo Fisher Scientific, Inc.
164.     Application-Specific Enhancements to Thermo Scientific HyPerforma Single-Use Bioreactor (S.U.B.); Presented by Mason S.

Thermo Fisher Scientific, Inc.
165.     12 Month Post Gamma Qualification of Single-Use pH Sensors in Single-Use Bioreactor, Mixer, and Fermenter Equipment; Presented by Mason S.

U.S. Food and Drug Administration
166.     Evaluation of the Differentiation Status of Neural Stem Cells Derived from Human iPSCs; Presented by Ge M.

UBE Industries, Ltd.
167.     Continuous Production of IgG, Virus, Recombinant Proteins and Exosomes Using a Novel Membrane Module System; Presented by Masahiko H.

Unchained Labs
168.     The New Hound: Three Lasers to ID It All; Presented by Robin S.

Unchained Labs
169.     Plug into Fast, Accurate Protein Quantification with Lunatic; Presented by Ross W.

University of California, San Diego
170.     Metabolic Model Predicts Growth Phenotypes of Mammalian Cell Culture; Presented by Matthew S.

University of Strasbourg
171.     Low-Shear Technology Towards Cell Culture Optimization; Presented by Thomas B.

Waters Corporation
172.     A Platform Method for the Molecular Mass Analysis of the Light Chains and Heavy Chains of Monoclonal Antibodies; Presented by Steven C.

Waters Corporation
173.     Meeting the Challenges of Implementing Accurate-Mass Mass Spectrometry for Biotherapeutic Development in Regulated/Non-Regulated Environments; Presented by John G.

Advanced Instruments
174.     Osmolality Is a Predictor for Model Based Real Time Monitoring of Concentration in Protein Chromatography; Presented by Kristeena W.

Genedata, Inc.
175.     Efficient Data Processing Workflows for In-Depth, MS-Based Glycoanalysis of Biopharmaceuticals; Presented by David B.

Genedata, Inc.
176.     Achieving Operational Efficiency in Bioprocess Development; Presented by Amanda F.

Genedata AG
177.     Integrated Sample and Data Management for Micro-Bioreactor Experiments; Presented by Lukasz G.

Genedata, Inc.
178.     A Platform Approach to Assess Developability Risks of Biologics; Presented by Andrew L.

Genedata, Inc.
179.     Automated Comprehensive Characterization and Quantification of Low-Abundance Sequence Variants in a Standard Monoclonal Antibody; Presented by John M.

Genedata, Inc.
180.     Accelerate Clinical Trial Entry by Automating Cell Line Development; Presented by Bernie E.

SCIEX
181.     A Quantitative Compliant Multi Attribute Methodology (MAM) LC/MS Workflow; Presented by Matthew S.

 

Presenting Monday through Tuesday

Bristol-Myers Squibb
201.     Sequence Variant Root Cause Identification in CHO Cell Line Generation; Presented by Todd R.

Seattle Genetics, Inc.
202.     Application of Design of Experiments (DoE) in the Development of a Process Specific HCP ELISA; Presented by Jenny W.

Thermo Fisher Scientific, Inc.
203.     Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems; Presented by Jian L.

 

Presenting Wednesday through Thursday

Biogen
301.     High-Throughput Screening of Adenovirus Infectivity for Accelerated Development; Presented by Annicka E.

Biogen
302.     Encapsidated rAAV Genome Characterization by Next-Generation Sequencing; Presented by Hui-wen L.

Bristol-Myers Squibb
303.     Small-Scale Tools for the Assessment of the Impact of Interfacial and Shear Stress on Biologic Drug Product; Presented by Maria O.

Bristol-Myers Squibb
304.     Charge Variants Separation by Free Flow Electrophoresis; Presented by Jun X.

Genedata, Inc.
305.     An Enterprise Software Platform to Streamline the Generation, Analysis, and Visualization of Genomic Data in Cell Line Development; Presented by Michael J.

Genedata, Inc.
306.     Adventitious Agent Detection of Biopharmaceuticals Using Next Generation Sequencing and Genedata Selector; Presented by Marcell V.

Leidos Biomedical Research, Inc.
307.     A Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing; Presented by Nagarathinam S.

LEUKOCARE AG
308.     Algorithm-Based Formulation Development with DoE Approach to Enable More Stable Liquid Formulations of Therapeutic Antibodies; Presented by Sabine H.

Massachusetts Institute of Technology
309.     Establishing a Correlation Between Automated and Manual Sampling in a Cell Culture Bioreactor; Presented by Christa N.

MilliporeSigma
310.     Development of a Chemically Defined Medium for Scale Up and a High-Producing HEK293T Clone for Transient Lentivirus Production; Presented by Daiva D.

Purilogics, LLC
311.     Case Study: New Affinity Membranes for the Rapid Isolation and Purification of Biologics; Presented by Graham T.

Purilogics, LLC
312.     Application of Novel Multimodal Anion-Exchange Membrane Chromatography Columns in a Two-Step mAb Purification Scheme - Aggregates and HCP Removal; Presented by Jinxiang Z.

Regeneron Pharmaceuticals, Inc.
313.     Microfluidic-Based Automated CHO HCP ELISA Enables HCP Quantification During High-Throughput Screening Studies with Small Samples Volumes and a Large Design Space; Presented by Samantha W.

SCIEX
314.     Method Optimization and Evaluation for RNA Purity Analysis Using CE-LIF Technology; Presented by James D.

Spheryx, Inc.
315.     Distinguishing Protein Aggregates from Contaminants in Viscous Mixtures with Holographic Video Microscopy; Presented by Laura P.

Tenaya Therapeutics
316.     AAV Comparability Between HEK293T and Sf9 Cell Production Platforms for Treatment of Heart Diseases; Presented by Charles F.

TetraScience
317.     Digital Bioprocessing Scale-Up: The Impact of Instrument and Software Integration; Presented by Jesus Z.

Thermo Fisher Scientific, Inc.
318.     ExpiSf™ Expression System: A Chemically Defined Baculovirus-Based System for Enhanced Protein and Virus Production in Sf9 Cells; Presented by Kenneth T.

Ultragenyx
319.     Improved Host-Cell Protein Clearance Utilizing Flow-Through Cation Exchange Membrane for AAV Purification; Presented by Mike D.

Ultragenyx
320.     Scale-Up and Conversion of an Adherent AAV Manufacturing Process to a Higher-Producing and Scalable Suspension Platform; Presented by

University of Miami
321.     Bioprocess Optimization of Nucleus Pulposus Derived Spheroid Production in Stirred-Tank Reactors; Presented by Daniel R.

University of Rochester Medical Center
322.     Cell Therapy Manufacturing the Upstate Stem Cell cGMP Facility; Presented by Luisa C.

US Pharmacopeia
323.     Characterization of USP Oligosaccharide System Suitability Mixture A and Mixture B Reference Standards; Presented by Tim G.